trastuzumab,pertuzumab
roche
['breast', 'phergain']
news from asco: results from the phergain trial suggest that patients with early-stage her2+ breast cancer experience improvements in 3-year survival when treated with her2 blockade plus a novel chemotherapy de-escalation strategy. #asco23 